CEL-SCI Corporation (CVM)
| Market Cap | 46.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.10M |
| Shares Out | 63.81M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 817,210 |
| Open | 0.680 |
| Previous Close | 0.765 |
| Day's Range | 0.655 - 0.739 |
| 52-Week Range | 0.490 - 3.230 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 12, 2025 |
About CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune sy... [Read more]
Financial Performance
Financial StatementsNews
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI highlights biological rationale for the use of Multikine in the Confirmatory Registration Head and Neck Cancer Study.
Stock Picks From Seeking Alpha's October 2024 New Analysts
In October, 42 new analysts joined Seeking Alpha, sharing diverse investment ideas and strategies, from biotech to real estate. Highlighted strong buy recommendations include MicroStrategy, CorMedix, ...
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025.
FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--FDA's ODAC decision on checkpoint inhibitors substantiates potential of Multikine to address major treatment gap for PD-L1 negative cancer patients.
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI selects Ergomed as CRO as it gears up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer.
CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESMO2024--CEL-SCI's Multikine Increased 5-Year Survival Rate in Locally Advanced Resectable Head & Neck Cancer Patients Deemed to be in the Treatment Group.
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESMO24--CEL-SCI to present new data for Multikine head & neck cancer immunotherapy at the European Society for Medical Oncology 2024 Congress.
The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--The UK's Medicines & Healthcare Products Regulatory Agency grants CEL-SCI a pediatric waiver for Multikine.
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports third quarter fiscal 2024 financial results, as well as key recent clinical and corporate developments.
CEL-SCI Announces Closing of $10.8 Million Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $10.8 million offering.
CEL-SCI Announces Pricing of $10.8 Million Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $10.8 million offering .
CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI's phase 3 population analysis for upcoming confirmatory registration study in head & neck cancer demonstrates well balanced patient population...
CEL-SCI Appoints Robert Watson as Chairperson of the Board
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI appoints Robert Watson as Chairperson of the Board.
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced the Company's Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled “Neoa...
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Dr. Giovanni Selvaggi, who has brought several oncology drugs to market, joins CEL-SCI as Clinical Advisor.
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports second quarter fiscal 2024 financial results.
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI receives FDA go-ahead for its confirmatory study of Multikine in the treatment of head & neck cancer.
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI appoints Mario Gobbo to its Board of Directors.
Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content
NEW YORK--(BUSINESS WIRE)--Channel V Media (CVM), a communications strategy and PR firm that builds market momentum for both established enterprises and emerging venture‑backed innovators, today annou...
CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI's LEAPS vaccine offers promising new paradigm to treat rheumatoid arthritis: published in Frontiers in Immunology.
CEL-SCI Corporation Issues Letter to Shareholders
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation issues letter to shareholders.
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results.
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $7.75 million public offering of common stock.
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces pricing of $7.75 million public offering of common stock.
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI completes commissioning of its Multikine manufacturing facility for commercial scale production of head & neck cancer drug.